ESSA Pharma Inc. (EPIX) Quick Liquidity

ESSA Pharma Inc. (EPIX) is establishing partnerships with leading oncology centers to conduct clinical trials of its developments. The stability of scientific research is guaranteed by distributing production capacities across secure zones. The current separate_ratio_quick is 68.78. The price trend demonstrates the company's expansion potential in the women's oncology segment through the implementation of the innovative drug EPI-7386.

EPIX: ESSA Pharma, Inc. Intermediate Coverage Ratio 07/04/2022 - 10/25/2025

Analytical breakdowns for ESSA Pharma Inc.

- share price and expert price forecast:

Stock Price essapharma.com|EPIX - Average Forecast Price

- market capitalization details:

Market Value ESSA Pharma Inc|EPIX - Value Adjusted for Debt and Cash

- book capitalization data:

Accounting Value per Share ESSA Pharma|EPIX - Accounting Value of Company|Market Cap to Net Assets Ratio essapharma.com|EPIX - Cumulative Company Assets

- business debt structure and liquidity details:

- earnings and valuation multiples information:

EPIX - Company Net Income

Basic company analysis:ESSA Pharma, Inc. - EPIX

Adherence to bioethical standards and ESG principles in the development of therapies by ESSA Pharma Inc. (EPIX) requires stable funding, making liquidity monitoring critical. This metric aggregates cash and accounts receivable, excluding inventories, to assess the company's ability to instantaneously settle its obligations. Analyzing the quick ratio allows an investor to distinguish real financial reserves from illiquid assets, revealing the balance between security and capital efficiency.

Analysis of competing companies